Cargando…
PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
Autores principales: | Arnan, Montserrat, Montesinos, Pau, de Botton, Stéphane, Recher, Christian, Wunderle, Lydia, Emig, Michael, Harstrick, Andreas, Pietzko, Kerstin, Pinto, Sheena, Ravenstijn, Paulien, Daver, Naval |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430174/ http://dx.doi.org/10.1097/01.HS9.0000974360.24047.92 |
Ejemplares similares
-
Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021) -
PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Daver, Naval, et al.
Publicado: (2023) -
Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019) -
P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
por: Kim, Won-Seog, et al.
Publicado: (2023) -
1884
Publicado: (1885)